AE Wealth Management’s ADMA Biologics ADMA Stock Holding History

AE Wealth Management’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$152K	Buy	+18,185	New	+$166K	﹤0.01%	1798
2023 Q1	–	Sell	-20,385	Closed	-$79.1K	–	1869
2022 Q4	$79.1K	Buy	+20,385	New	+$62.9K	﹤0.01%	1734
2021 Q3	–	Sell	-100,504	Closed	-$161K	–	1617
2021 Q2	$161K	Buy	100,504 +504	+0.5%	+$887	﹤0.01%	1516
2021 Q1	$176K	Sell	100,000 -10,500	-10%	-$24K	﹤0.01%	1420
2020 Q4	$215K	Buy	110,500 +8,500	+8%	+$17.9K	﹤0.01%	1259
2020 Q3	$244K	Buy	102,000 +2,000	+2%	+$5.48K	﹤0.01%	1109
2020 Q2	$293K	Buy	+100,000	New	+$287K	﹤0.01%	1027

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

AE Wealth Management's ADMA Position: Q2 2026 in Review

AE Wealth Management opened a new position in ADMA Biologics (ADMA) in Q2 2026: 18,185 shares worth $152K. The stake represents ﹤0.01% of the portfolio and ranks #1798 among its holdings. This is a return to the name: AE Wealth Management previously reported a position in ADMA as recently as Q4 2022.

AE Wealth Management first reported a position in ADMA in Q2 2020 and has held it in 7 quarters since. The position peaked at $293K in Q2 2020. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

AE Wealth Management held 18,185 shares of ADMA Biologics worth $152K as of Q2 2026.
ADMA Biologics was a new AE Wealth Management position in Q2 2026.
ADMA Biologics made up ﹤0.01% of AE Wealth Management's portfolio in Q2 2026, its #1798 holding.
AE Wealth Management first reported a position in ADMA Biologics in Q2 2020 and has held it in 7 quarters since.
AE Wealth Management's ADMA Biologics position peaked at $293K in Q2 2020.
322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on AE Wealth Management's 13F filing for Q2 2026, filed 3 Aug 2026.